Shahid Iqbal

Dr. Shahid Iqbal

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SASaeed Anwar
Saeed Anwar
Wajid RehmanWajid Rehman
Wajid Rehman
RHRafaqat Hussain
Rafaqat Hussain
SKShoaib Khan
Shoaib Khan
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
Muhammad HanifMuhammad Hanif
Muhammad Hanif
Alzheimer’s disease (AD) is a progressive neurological illness that is distinguished clinically by cognitive and memory decline and adversely affects the people of old age. The treatments for this disease gained much attention and have prompted increased interest among researchers in this field. As a springboard to explore new anti-Alzheimer’s chemical prototypes, the present study was carried out for the synthesis of benzoxazole-oxadiazole analogues as effective Alzheimer’s inhibitors. In this research work, we have focused our efforts to synthesize a series of benzoxazole-oxadiazole (1–19) and evaluating their anti-Alzheimer properties. In addition, the precise structures of synthesized derivatives were confirmed with the help of various spectroscopic techniques including 1H-NMR, 13C-NMR and HREI-MS. To find the anti-Alzheimer potentials of the synthesized compounds (1–19), in vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), inhibitory activities were performed using Donepezil as the reference standard. From structure-activity (SAR) analysis, it was confirmed that any variation found in inhibitory activities of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes were due to different substitution patterns of substituent(s) at the variable position of both acetophenone aryl and oxadiazole aryl rings. The results of the anti-Alzheimer assay were very encouraging and showed moderate to good inhibitory potentials with IC50 values ranging from 5.80 ± 2.18 to 40.80 ± 5.90 µM (against AChE) and 7.20 ± 2.30 to 42.60 ± 6.10 µM (against BuChE) as compared to standard Donepezil drug (IC50 = 33.65 ± 3.50 µM (for AChE) and 35.80 ± 4.60 µM (for BuChE), respectively. Specifically, analogues 2, 15 and 16 were identified to be significantly active, even found to be more potent than standard inhibitors with IC50 values of 6.40 ± 1.10, 5.80 ± 2.18 and 6.90 ± 1.20 (against AChE) and 7.50 ± 1.20, 7.20 ± 2.30 and 7.60 ± 2.10 (against BuChE). The results obtained were compared to standard drugs. These findings reveal that benzoxazole-oxadiazole analogues act as AChE and BuChE inhibitors to develop novel therapeutics for treating Alzheimer’s disease and can act as lead molecules in drug discovery as potential anti-Alzheimer agents.

1 January 2020 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SIShahid Iqbal
Shahid Iqbal
XCXiao Dong Chen
Xiao Dong Chen
TKTimothy V. Kirk
Timothy V. Kirk
HHHe Huang
He Huang

30 October 2024 in Food Hydrocolloids
Verified
Journal Article
Closed access
RPRonggang Pan
Ronggang Pan
SIShahid Iqbal
Shahid Iqbal
NWNi Wang
Ni Wang
Peng WuPeng Wu
Peng Wu
HCHaozhi Chen
Haozhi Chen
XCXiao Dong Chen
Xiao Dong Chen

3 June 2023 in Journal of Water Process Engineering
Verified
Journal Article
Closed access
SIShahid Iqbal
Shahid Iqbal
JLJianjun Liu
Jianjun Liu
HMHecheng Ma
Hecheng Ma
WLWenqi Liu
Wenqi Liu
SZShengli Zuo
Shengli Zuo
MMMuhammad Mushtaq
Muhammad Mushtaq

12 June 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
HCHaozhi Chen
Haozhi Chen
SIShahid Iqbal
Shahid Iqbal
Peng WuPeng Wu
Peng Wu
RPRonggang Pan
Ronggang Pan
NWNi Wang
Ni Wang
XCXiao Dong Chen
Xiao Dong Chen

15 January 2025 in Journal of Food Engineering
Verified
Journal Article
Closed access
RPRonggang Pan
Ronggang Pan
SIShahid Iqbal
Shahid Iqbal
NWNi Wang
Ni Wang
HCHaozhi Chen
Haozhi Chen
RBRizwan Ahmed Bhutto
Rizwan Ahmed Bhutto
Peng WuPeng Wu
Peng Wu